Media coverage about Ignyta (NASDAQ:RXDX) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ignyta earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.5862990450745 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
RXDX has been the subject of a number of recent research reports. SunTrust Banks lowered Ignyta from a “buy” rating to a “hold” rating and increased their target price for the company from $25.00 to $27.00 in a research note on Tuesday, December 26th. ValuEngine upgraded Ignyta from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Cantor Fitzgerald reiterated a “hold” rating and issued a $27.00 target price on shares of Ignyta in a research note on Friday, February 9th. Jefferies Group lowered Ignyta from a “buy” rating to a “hold” rating and set a $27.00 target price for the company. in a research note on Friday, December 22nd. Finally, Ladenburg Thalmann lowered Ignyta from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 26th. Seven analysts have rated the stock with a hold rating and one has given a buy rating to the company. Ignyta presently has an average rating of “Hold” and an average target price of $27.00.
Shares of NASDAQ RXDX opened at $26.95 on Friday. Ignyta has a fifty-two week low of $5.80 and a fifty-two week high of $27.10. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.07 and a quick ratio of 6.07.
WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/15/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-ignyta-rxdx-stock-price.html.
Ignyta Company Profile
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.